

Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka K, Fujii N, Kondo E, Shinagawa K, Tanaka T, Takeuchi K, Teshima T, Tanimoto M.	Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.	Biol Blood Marrow Transplant.	20(2)	183-191	2014
Fujiwara H, Maeda Y, Kobayashi K, Nishimori H, Matsuoka K, Fujii N, Kondo E, (Tanaka T, Chen L, Azuma M, Yagita H), Tanimoto M.	PD-1 pathway in host tissues ameliorates Th17/Th1 mediated experimental chronic graft-versus-host disease	J Immunol.	193(5)	2565-73.	2014
Fujii N, (Nakase K, Asakura S, Matsuoka K, Nawa Y, Sunami K), Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, (Hara M), Tanimoto M.	Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.	Int J Hematol.	99(5)	644-51	2014
Asano T, Fujii N, Nishimori H, Fujii K, Matsuoka K, (Ichimura K, Hamada T), Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M.	Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation.	Springerplus.	3:3		Springerplus
Okamoto S, Fujiwara H, Nishimori H, Matsuoka K, Fujii N, Kondo E, (Tanaka T, Yoshimura A), Tanimoto M, Maeda Y.	Anti-IL-12/23 p40 Antibody Attenuates Experimental Chronic Graft-versus-Host Disease via Suppression of IFN-gamma/IL-17 Producing Cells.	J Immunol.	194	1357-1363.	J Immunol.

Sakata-Yanagimoto M Enami T Yokoyama Y <u>Chiba S</u>	Disease-Specific Mutations in Mature Lymphoid Neoplasms-Recent Advances.	Cancer Sci	105(6)	623-629	2014
Lee SY Okoshi Y Kurita N Seki M Yokoyama Y Maie K Hasegawa Y <u>Chiba S</u>	Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen.	Oncol Res Treat	37(7-8)	378-383	2014
Maie K Yokoyama Y Kurita N Minohara H Yanagimoto S Hasegawa Y Homma M <u>Chiba S</u>	Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome.	SpringerPlus	3	501(eCollection)	2014
Kato T Sakata-Yanagimoto M Nishikii H Miyake Y Yokoyama Y Asabe Y Kamada Y Ueno M Obara N Suzukawa K Hasegawa Y Kitabayashi I Uchida K Hirao A Yagita H Kageyama R <u>Chiba S</u>	Hes1 suppresses acute myeloid leukemia development through FLT3 repression.	Leukemia	Epub ahead of print		2014

<p>Nakamoto-Matsubara R Sakata-Yanagimoto M Enami T Yoshida K Yanagimoto S Shiozawa Y Nanmoku T Satomi K Muto H Obara N Kato T Kurita N Yokoyama Y Izutsu K Ota Y Sanada M Shimizu S Komeno T Sato Y Ito T Kitabayashi I Takeuchi K Nakamura N Ogawa S <u>Chiba S</u></p>	<p>Detection of the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and related lymphomas using quantitative allele-specific PCR.</p>	<p>PLoS One</p>	<p>9(10)</p>	<p>e109714</p>	<p>2014</p>
<p>Muto H Sakata-Yanagimoto M Nagae G Shiozawa Y Miyake Y Yoshida K Enami T Kamada Y Kato T Uchiba K Nanmoku T Obara N Suzukawa K Sanada M Nakamura N Aburatani H Ogawa S <u>Chiba S</u></p>	<p>Reduced TET2 Function Leads to T-cell Lymphoma with Follicular Helper T cell-like Features in mice.</p>	<p>Blood Cancer J</p>	<p>4</p>	<p>e264</p>	<p>2014</p>

Truong P Sakata-Yanagimoto M Yamada M Nagae G Enami T Nakamoto-Matsubara R Aburatani H Chiba S	Age-Dependent Decrease of DNA Hydroxymethylation in Human T Cells.	J. Clin. Exp. Hematopathol	in press		
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.	Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-First study of Kanto CML Study Group.	Am J Hematol	Epub ahead of print		2014
Sakata-Yanagimoto M, Chiba S.	Notch2 signaling in mast cell development and distribution in the intestine.	Methods Mol Biol	1220	79-89	2015

北村俊雄 井上大地 中原史雄 大河内直子 加藤奈緒子 戸上勝仁 内田智之 鍵山侑希 川畑公人 永瀬玲奈 堀川小百合 林 康貴 齋賀真言 伊沢久未 沖 俊彦 千葉 滋 原田結花 原田浩徳 北浦次郎	骨髓系造血器腫瘍発症 の分子機構	臨床血液	(55) 10	1715-1723	2014
Kawakami T He J Morita H Yokoyama K Kaji H Tanaka C Suemori S Tohyama K Tohyama Y	Rab27a is essential for the formation of neutrophil extracell ular traps (NETs) i n neutrophil-like dif ferentiated HL60 cel ls.	PLoS One	9	e84704	2014
Rhyasen GW Wunderlich M Tohyama K Garcia-Manero G Mulloy JC Starczynowski DT	An MDS xenograft model utilizing a pa tient-derived cell lin e.	Leukemia	28	1142-1145	2014

Hu X-M Yuan B Tanaka S Song M-M Onda K Tohyama K Zhou A-X Toyoda H Hirano T	Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.	Hematology	19	352-360	2014
Hayashi K Tasaka T Hirose T Furukawa S Kohguchi K Matsuhashi Y Wada H Tohyama K Sugihara T	Delayed false elevation of circulating tacrolimus concentrations after cord blood transplantation in a patient with myelodysplastic syndrome.	Intern Med	53	2635-2638	2014
通山薫	〔特集 臨床検査—ここまで進んだ検査の世界〕各論 血液（赤血球と白血球）	診断と治療	102	93-99	2014
通山薫	〔特集 造血器疾患—最新の治療戦略（赤血球系疾患）〕骨髄異形成症候群：最新の治療戦略	臨床血液	55	12-21	2014
近藤敏範 通山薫	検査UPDATE. 骨髄異形成症候群の診断手順	SRL宝函	34(4)	4-14	2014
末盛晋一郎 通山薫	〔特集 もう見逃さない！迷わない！非血液専門医のための血液診療〕汎血球減少	medicina	51	452-455	2014
通山薫	〔技術講座 血液 step up編〕骨髄異形成症候群（MDS）における形態異常	検査と技術	42	1212-1219	2014
通山薫	〔特集 難治性貧血 - 診断と病態・治療の進歩 - 〕骨髄異形成症候群の病態解明と診断の進歩	最新医学	69	2125-2133	2014

Fujiwara T, Okamoto K, Niikuni R, Takahashi K, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Nakamura Y, Nakajima M, Tanaka T, Harigae H. et al.	Effect of 5-aminolevulinic acid on erythropoiesis: A preclinical in vitro characterization for the treatment of congenital sideroblastic anemia.	Biochem Biophys Res Commun.	454	102-8.	2014
Daisuke Okamura, Akira Matsuda, Maho Ishikawa, Tomoya Maeda, Ken Tanae, Mika Kohri, Naoki Takahashi, Nobutaka Kawai, Norio Asou, Masami Bessho.	Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine	Leukemia Research Reports	3巻1号	24-27	2014
松田晃	骨髄異形成症候群の治療の進歩	最新医学	69巻11号	2134-2141	2014
松田晃	MDSの形態異常と遺伝子異常	病理と臨床	33巻2号	145-149	2015
松村 到	慢性期の慢性骨髄性白血病の治療	臨床血液	55	145-151	2014
松村 到	慢性骨髄性白血病の治療	日本内科学会雑誌	103	2261-2268	2014
田中宏和、松村 到	骨髄不全症における鉄過剰の病的意義	血液内科	68	572-578	2014
田中宏和、松村 到	骨髄系の白血病幹細胞	医学のあゆみ	250	5-9	2014
嶋田高広、松村 到	緑膿菌の免疫回避機構	Jpn.J.Clin. Immunol.	37	33-41	2014
平瀬主税、田中宏和、松村 到	慢性骨髄性白血病におけるELN2013	血液内科	68	399-404	2014
宮武淳一、平瀬主税、松村 到	慢性骨髄性白血病	臨床腫瘍プラクティス	10	43-48	2014
Tanimura A, Shibayama H, Hamanaka Y, Fujita N, Ishibashi T, Sudo T, Yokota T, Ezoe S, Tanaka H, Matsumura I, Oritani K, Kanakura Y.	The anti-apoptotic gene Anamorsin is essential for both autonomic and extrinsic regulation of murine fetal liver hematopoiesis.	Exp Hematol	42	410-422	2014

Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kingosugi S, Fuchida S, Kobayashi M, Kaneko H, Uoshima N, Ieshii K, Nomura S, Taniwaki M, Takaori-Kondo A, Shimazaki C, Tsudo M, Hingono M, Matsumura I, Kanakura Y; Kansai Myeloma Forum Investigators.	Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.	Int J Hematol.	99	441-449	2014
Rai S, Tanaka H, Suzuki M, Ogoh H, Taniguchi Y, Morita Y, Shimada T, Tanimura A, Matsui K, Yokota T, Oritani K, Tanabe K, Watanabe T, Kanakura Y, Matsumura I.	Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells.	PLoS One.	9	e109441	2014
Sakurai M, Kunimoto H, Watanabe N, Fukuchi Y, Yuasa S, Yamazaki S, Nishimura T, Sadahira K, Fukuda K, Okamoto H, Nakauchi H, Morita Y, Matsumura I, Kudo K, Ito E, Ebihara Y, Tsuji K, Harada Y, Harada H, Okamoto S, Nakajima H.	Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.	Leukemia.	28	2344-2354	2014
Yabe M, Morimoto T, Shimizu T, Koike T, Ohtsubo K, Fukumura A, Kato S, <u>Yabe H.</u>	Feasibility of marrow harvesting from pediatric sibling donors without hematopoietic growth factors and allotransfusion.	Bone Marrow Transplant	49	921-926	2014
Kobayashi R, <u>Yabe H.</u> , Kikuchi A, Kudo K, Yoshida N, Watanabe K, Muramatsu H, Takahashi Y, Inoue M, Koh K, Inagaki J, Okamoto Y, Sakamaki H, Kawak K, Kato K, Suzuki R, Kojima S.	Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia.	Biol Blood Marrow Transplant.	20	1145-1149	2014

Sakaguchi H, Nishio N, Hama A, Kawashima N, Wang X, Narita A, Doisaki S, Xu Y, Muramatsu H, Yoshida N, Takahashi Y, Kudo K, Moritake H, Nakamura K, Kobayashi R, Ito E, <u>Yabe H</u> , Ohga S, Ohara A, Kojima S.	Japan Childhood Aplastic Anemia Study Group. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia.	Haematologica	99	1312-1316	2014
Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A, <u>Yabe H</u> , Horibe K, Hanada R, Imaizumi M, Hayashi Y, Hamamoto K, Kobayashi R, Kudo K, Shimada A, Miyamura T, Moritake H,	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.	Int J Hematol.	100	17-179	2014
Kato M, Yoshida N, Inagaki J, Maeba H, Kudo K, Cho Y, Kurosawa H, Okimoto Y, Tauchi H, <u>Yabe H</u> , Sawada A, Kato K, Atsuta Y, Watanabe K.	Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms.	Pediatr Blood Cancer	61	1860-1866	2014
Patel P, Suzuki Y, Tanaka A, <u>Yabe H</u> , Kato S, Shimada T, Mason RW, Orii KE, Fukao T, Orii T, Tomatsu S.	Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.	Mol Genet Metab	1	184-196	2014

Sato Y, Kurosawa H, Fukushima K, Okuya M, <u>Yabe H</u> , Arisaka O.	Necessary stem cell transplantation using myeloablative therapy for myelodysplastic syndrome with progression of genotypic abnormalities and TP53 dysfunction in a young adult.	Pediatr Transplant	18	E255-257	2014
Yoshida N, Kobayashi R, <u>Yabe H</u> , Kosaka Y, Yagasaki H, Watanabe KI, Kudo K, Morimoto A, Ohga S, Muramatsu H, Takahashi Y, Kato K, Suzuki R, Ohara A, Kojima S.	First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor vs. immunosuppressive therapy	Haematologica	99	1784-1791	2014
Goto H, Kaneko T, Shioda Y, Kajiwara M, Sakashita K, Kitoh T, Hayakawa A, Miki M, Kato K, Ogawa A, Hashii Y, Inukai T, Kato C, Sakamaki H, <u>Yabe H</u> , Suzuki R, Kato K.	Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome	Pediatr Blood Cancer	62	148-152	2014
Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J, <u>Yabe H</u> , Goto H, Adachi S, Hayakawa A, Takeshita Y, Sawada A, Atsuta Y, Kato K.	Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell	Br J Haematol	doi: 10.1111/bjh.13174. [Epub ahead of print]		2014

Tanjuakio J, Suzuki Y, Patel P, Yasuda E, Kubaski F, Tanaka A, <u>Yabe H</u> , Mason RW, Montaña AM, Orii KE, Orii KO, Fukao T, Orii T, Tomatsu S.	Activities of daily living in patients With Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation.	Mol Genet Metab	doi: 10.1016/j.ymgme.2014.11.002. [Epub ahead of print]		2014
Yabe M, Ohtsuka Y, Watanabe K, Inagaki J, Yoshida N, Sakashita K, Kakuda H, <u>Yabe H</u> , Kurosawa H, Kudo K, Manabe A.	Japanese Pediatric Myelodysplastic Syndrome Study Group. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.	Int J Hematol.	DOI 10.1007/s12185-014-1715-7		2014
Tanino Y, <u>Yamaguchi H</u> , et al.	Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required?	Eur Respir J	44(1)	270	2014
Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, Iwasaki H, Miyamoto T, Hill GR, Akashi K, Teshima T.	Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning.	Bone Marrow Transplant	49(1)	110-115	2014
Shono Y, Shiratori S, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, Kondo T, Hashimoto D, Fujimoto K, Endo T, Nishio M, Hashino S, Matsuno Y, Matsushima K, Tanaka J, Imamura M, Teshima T.	Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation.	Biol Blood Marrow Transplant	20(4)	495-500	2014

Shiratori S, Wakasa K, Okada K, Sugita J, Akizawa K, Shigematsu A, Hashimoto D, Fujimoto K, Endo T, Kondo T, Shimizu C, Hashino S, Teshima T	Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience.	Clin Transplant	28(6)	656-661	2014
Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, Koda K, Iyama S, Kuroda H, Tsutsumi Y, Imamura M, Teshima T	High level of serum soluble interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia.	Biol Blood Marrow Transplant	20(6)	801-805	2014
Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, Kamezaki K, Oku S, Henzan H, Takase K, Matsushima T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K, Teshima T	The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group.	Intern Med	53(12)	1315-1320	2014
杉田純一 小杉瑞葉 豊嶋崇徳	移植後シクロホスファミドを用いたHLA半合致移植の現状と課題	日本造血細胞移植学会雑誌	4(1)	9-22	2015
Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watanabe K, Kohno A, Kasai M, Kato C, Iwada H, Naoe T, Miyamura K, Murata M; for the Nagoya Blood and Marrow Transplantation Group.	Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.	Ann Hematol	In press		2015

Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M.	Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody.	J Immunother	38	62-70	2015
Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.	Target Antigen Density Governs the Efficacy of Anti-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells.	J Immunol	194	911-920	2015
Hayakawa F, Sakuraba T, Yujiri T, Kondou E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suehara S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG).	Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.	Blood Cancer J	4	e252	2014
Shimada K, Tomita A, Saito S, Kiyoi H.	Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.	Br J Haematol	166	455-457	2014

<p>Kihara R, Nagata Y, <u>Kiyoi H</u>, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Utsui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraiishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T.</p>	<p>Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.</p>	<p>Leukemia</p>	<p>28</p>	<p>1586-1595</p>	<p>2014</p>
<p>Ono T, Takeshita A, Kishimoto Y, <u>Kiyoi H</u>, Okada M, Yamaguchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iriwanaga M, Asou N, Naoe T; The Japan Adult Leukemia Study Group.</p>	<p>Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with high initial white blood cell counts.</p>	<p>Cancer Sci.</p>	<p>105</p>	<p>91-104</p>	<p>2014</p>
<p>Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, <u>Kiyoi H</u>, Asano N, Nakamura S, Kinoshita T, Naoe T.</p>	<p>De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity.</p>	<p>Cancer Sci</p>	<p>105</p>	<p>35-43</p>	<p>2014</p>

VI. 研究成果の刊行物・別刷

ARTICLE

Received 29 Jan 2014 | Accepted 21 Jul 2014 | Published 27 Aug 2014

DOI: 10.1038/ncomms5770

Recurrent *CDC25C* mutations drive malignant transformation in FPD/AML

Akihide Yoshimi^{1,*}, Takashi Toya^{1,*}, Masahito Kawazu², Toshihide Ueno³, Ayato Tsukamoto¹, Hiromitsu Iizuka¹, Masahiro Nakagawa¹, Yasuhito Nannya¹, Shunya Arai¹, Hironori Harada⁴, Kensuke Usuki⁵, Yasuhide Hayashi⁶, Etsuro Ito⁷, Keita Kirito⁸, Hideaki Nakajima⁹, Motoshi Ichikawa¹, Hiroyuki Mano³ & Mineo Kurokawa¹

Familial platelet disorder (FPD) with predisposition to acute myelogenous leukaemia (AML) is characterized by platelet defects with a propensity for the development of haematological malignancies. Its molecular pathogenesis is poorly understood, except for the role of germline *RUNX1* mutations. Here we show that *CDC25C* mutations are frequently found in FPD/AML patients (53%). Mutated *CDC25C* disrupts the G2/M checkpoint and promotes cell cycle progression even in the presence of DNA damage, suggesting a critical role for *CDC25C* in malignant transformation in FPD/AML. The predicted hierarchical architecture shows that *CDC25C* mutations define a founding pre-leukaemic clone, followed by stepwise acquisition of subclonal mutations that contribute to leukaemia progression. In three of seven individuals with *CDC25C* mutations, *GATA2* is the target of subsequent mutation. Thus, *CDC25C* is a novel gene target identified in haematological malignancies. *CDC25C* is also useful as a clinical biomarker that predicts progression of FPD/AML in the early stage.

¹Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ²Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ³Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ⁴Department of Hematology, Juntendo University School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. ⁵Department of Hematology, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo 141-8625, Japan. ⁶Department of Hematology/Oncology, Gunma Children's Medical Center, 779 Simohakoda, Kitaakebonocho, Shibukawa-shi, Gunma 377-8577, Japan. ⁷Department of Pediatrics, Graduate School of Medicine, Hirosaki University, 53 Honmachi, Hirosaki-shi, Aomori 036-8563, Japan. ⁸Department of Hematology and Oncology, University of Yamanashi, 1110 Simokawakita, Chuou-shi, Yamanashi 409-3898, Japan. ⁹Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.K. (email: kurokawa-tyk@umin.ac.jp).

Familial platelet disorder (FPD)/acute myelogenous leukaemia (AML) (MIM601399) is an autosomal dominant disorder with inherited thrombocytopenia, abnormal platelet function and a lifelong risk of the development of a variety of haematological malignancies¹, such as AML, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms. Although inherited *RUNX1* mutations are the cause of the congenital thrombocytopenia, it remains unclear whether a mutation in *RUNX1*, which is generally known to have a dominant-negative effect^{2–4}, is sufficient to induce the development of haematological malignancies in individuals with FPD/AML. It is also not known whether additional gene mutations are required for the transformation, and, if so, which genes are involved. Given that only 40% of FPD/AML patients develop these neoplasms⁵ and that a relatively long period is required for subsequent *RUNX1* mutation-mediated development of neoplasms in FPD/AML, the secondary genetic events may function as a driver to promote malignant transformation. We reasoned that identifying gene mutations responsible for the malignant transformation of FPD/AML would provide indispensable information for addressing these questions. However, only about 30 pedigrees with FPD/AML have been reported so far, and the rarity of this disorder has impeded the establishment of clinical diagnostic criteria and the clinical improvement to refine cancer therapy and to identify biomarkers that would allow detection of patients at risk for the onset of malignancies in FPD/AML.

We collected DNA samples and clinical information of 73 individuals, belonging to 57 pedigrees, who have a history of familial thrombocytopenia and/or haematological malignancies, with the aim of identifying pedigrees with FPD/AML and uncovering recurrent mutations that drive the malignant transformation. Next-generation sequencing and single-cell sequencing strategy suggest that somatic mutation in *CDC25C* may be one of the early genetic events for leukaemic initiation in FPD/AML, and further stepwise acquisition of mutations such as *GATA2* leads to FPD/AML-associated leukaemic progression. These observations shed light on a part of leukemogenesis in FPD/AML.

Results

A novel gene target in haematological disorders. Thirteen patients in 7 pedigrees were diagnosed as having FPD/AML after screening for germline *RUNX1* mutations in 73 index patients; 7 of the 13 patients had developed haematological malignancies, while the other 6 only showed thrombocytopenia (Table 1).

Most of the detected *RUNX1* mutations were point mutation in Runt homology domain or frame-shift mutation that lost transactivation domain, consistent with the previous reports^{2,4}. As haploinsufficiency of *RUNX1* might cause familial thrombocytopenia with propensity to develop AML¹, we also examined whether the pedigrees have *RUNX1* loss of heterozygosity (LOH) or not. A synchronized quantitative-PCR method⁶ and single-nucleotide polymorphism (SNP) sequencing detected no case with LOH in *RUNX1* in our cohort (Supplementary Fig. 1 and detailed in Methods). To systematically identify additional genetic alterations, we utilized whole-exome sequencing for two individuals from the same FPD/AML pedigree who shared a common *RUNX1*_p.Phe303fs mutation and who had developed MDS (subject 20) or myelofibrosis (subject 21) at the age of 37 and 17 years, respectively. In both these patients, the disease had progressed to AML⁷. Validation by Sanger sequencing and/or targeted deep sequencing of candidate mutations in paired tumour/normal DNA samples confirmed 10 (subject 20) and 8 (subject 21) somatically acquired nonsynonymous mutations (Table 2; Supplementary Figs 2–4; Supplementary Methods). Surprisingly, both patients carried the identical somatic *CDC25C* mutation (p.Asp234Gly), which had not been reported previously in human cancers (Fig. 1a,b). Prompted by this finding, we investigated *CDC25C* mutations in other FPD/AML cases by deep sequencing. In total, four of seven affected patients with haematological malignancies had *CDC25C* mutations, of which three carried the same p.Asp234Gly mutation. Moreover, *CDC25C* mutations were detected in an additional three FPD/AML patients who had not yet developed haematological malignancies, although the variant allele fractions (VAFs) were much lower in this group of patients than in those who had already developed haematological malignancies (Fig. 1c; Table 1). Thus, 7 of the 13 FPD/AML patients (53%) harboured a *CDC25C* mutation. *CDC25C* was also screened for mutations in 90 sporadic MDS and 53 AML patients, including 13 MDS and 3 AML cases who carried *RUNX1* mutations. No *CDC25C* mutations were identified in the 90 sporadic cases, except for the p.Ala344Val in an MDS patient bearing a *RUNX1* mutation, indicating that *CDC25C* mutations were significantly associated with germline, but not with somatic *RUNX1* mutations ($P=0.004$; Supplementary Fig. 5; Supplementary Table 1).

Clonal evolution of FPD/AML. Deep sequencing of individual mutations that had been detected by whole-exome sequencing

Table 1 | Mutational status of *CDC25C* in FPD/AML patients.

Pedigree number	Subject number	<i>RUNX1</i> mutation	Disease status	Age, years*	<i>CDC25C</i> mutation	VAF (%)
18	20	p.Phe303fs	MDS/AML	37/38	p.Asp234Gly	31.7/45.8
	21		MF/AML	17/18	p.Asp234Gly	31.1/39.0
19	22	p.Arg174*	AML	41	p.His437Asn	39.7
	54	p.Ser140Asn	MDS	25	—	—
32	66		AML	56	p.Asp234Gly	24.2
	38	p.Leu445Pro	HCL	72	—	—
16	18	p.Thr233fs	Thrombocytopenia	—	p.Asp234Gly	5.9
	53	p.Gly262fs	MDS	12	—	—
57	63		Thrombocytopenia	—	—	—
	67		Thrombocytopenia	—	—	—
	71	p.Gly172Glu	Pancytopenia [†]	—	p.Asp234Gly	8.3
	72		Thrombocytopenia	—	—	—
	73		Thrombocytopenia	—	p.Lys233Glu	1.8

AML, acute myeloid leukemia; FPD, familial platelet disorder; HCL, hairy cell leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; VAF, variant allele fraction.

*Age at the time of diagnosis of each haematological malignancy is shown.

[†]Thrombocytopenia, leukopenia and iron-deficiency anemia were diagnosed.

Table 2 | Validated somatic mutations.

Gene symbol	Ref seq_no.	Amino-acid change	Position (hg19)	Base change	Mutation type	SIFT prediction	VAF at MDS/MF (%)	VAF at AML (%)
<i>Subject 20</i>								
AGAP4	NM_133446	p.Arg484Cys	g.chr10:46321905	C->T	Missense	Damaging	13.2	11.5
CDC25C	NM_001790	p.Asp234Gly	g.chr5:137627720	A->G	Missense	Damaging	31.7	45.8
CHEK2	NM_007194	p.Arg406His	g.chr22:29091740	G->A	Missense	Tolerated	14.6	11.1
COL9A1	NM_001851	p.Gly878Val	g.chr6:70926733	G->T	Missense	Damaging	9.6	26.4
DTX2	NM_001102594	p.Pro74Arg	g.chr7:76110047	C->G	Missense	Damaging	18.3	11.2
FAM22G	NM_001170741	p.Ser508Thr	g.chr9:99700727	T->A	Missense	Tolerated	10.2	27.6
GATA2	NM_001145661	p.Leu321His	g.chr3:128202758	T->A	Missense	Damaging	0.0	28.1
LPP	NM_001167671	p.Val538Met	g.chr3:188590453	G->A	Missense	Damaging	9.7	28.8
RP1L1	NM_178857	p.Ser215fs	g.chr8:10480295	insC	Frameshift	Damaging	14.2	12.7
SIGLEC9	NM_014441	p.Ser437Gly	g.chr19:51633253	A->G	Missense	Tolerated	27.4	42.5
<i>Subject 21</i>								
ANXA8L1	NM_001098845	p.Val281Ala	g.chr10:48268018	T->C	Missense	Damaging	30.8	36.8
CDC25C	NM_001790	p.Asp234Gly	g.chr5:137627720	A->G	Missense	Damaging	31.1	39.1
DENND5A	NM_001243254	p.Arg320Ser	g.chr11:9215218	A->C	Missense	Damaging	29.5	37.3
FER	NM_005246	p.Tyr634Cys	g.chr5:108382876	A->G	Missense	Damaging	1.4	30.4
FNDC1	NM_032532	p.Arg189Cys	g.chr6:159636081	C->T	Missense	Damaging	29.3	35.9
OR8U1	NM_001005204	p.Asn175Ile	g.chr11:56143623	A->T	Missense	Damaging	30.0	34.1
PIDD	NM_145886	p.Arg342Cys	g.chr11:802347	C->T	Missense	Damaging	3.3	28.3
ZNF614	NM_025040	p.Glu202Gly	g.chr19:52520246	A->G	Missense	Damaging	28.7	33.7

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; SIFT, sorting intolerant from tolerant; VAF, variant allele fraction.

allowed accurate determination of their VAFs; on this basis, we could establish an inferred model of clonal evolution in terms of individual mutations in subjects 20 and 21 (Fig. 2a,b; Supplementary Fig. 6a,b). Intratumoral heterogeneity was evident at both MDS and AML phases in subject 20. According to the predicted model, a founding clone with a *CDC25C* mutation acquired additional mutations in *COL9A1*, *FAM22G* and *LPP* (group A), followed by the emergence of a *GATA2* mutation (group B), which was associated with leukaemic transformation, whereas the size of another subclone, defined by mutations in *CHEK2* and three other genes (group C), was unchanged. To validate this hierarchical model, single-cell genomic sequencing was performed using genomic DNA of 63 bone marrow cells from subject 20 when the patient was in the AML phase. Assuming that all cells harbour the *RUNX1* mutation, the false-negative rate of the procedure reached 35%, possibly due to biased allele amplification (Online Methods). However, this technique successfully demonstrated that the group A/B and group C mutations were mutually exclusive (Fig. 2c; Supplementary Table 2). To statistically evaluate this possibility, we assumed two hypotheses (H_0 : the mutational status of genes in group A/B and group C is independent; H_1 : mutations in group A/B and group C are mutually exclusive) and calculated each probability distribution (P_i : probability that the current results as shown in Fig. 2c were obtained under the hypothesis H_i). Our mutational profile data were achieved with a much higher likelihood under H_1 than H_0 (Supplementary Fig. 7 and detailed in Supplementary Methods). Similarly, the clonal architecture for subject 21 was portrayed in Fig. 2b and Supplementary Fig. 6b. In both scenarios, *CDC25C* mutations seemed to represent a founding mutation with the highest VAF, suggesting that the *CDC25C* mutation contributed to the establishment of a founding tumour population as an early genetic event, whereas progression to AML seemed to be accompanied by the appearance of additional mutations, indicating a multistep process in leukemogenesis.

Along with the somatic mutations found in subjects 20 and 21, a *GATA2* mutation was also identified in subject 22 (Fig. 3a). This

patient developed AML with multilineage dysplasia, which led to the diagnosis of AML – MRC (myelodysplasia-related changes). Remission-induction therapies were only partially effective and the blast cell count was reduced from 54 to 5.6%, while dysplastic features persisted (Fig. 3b; Supplementary Fig. 8). Allogeneic stem cell transplantation was successfully performed from a human leukocyte antigen-matched unrelated donor and durable complete remission, with 100% donor chimerism, was achieved. During treatment, the VAF of the *GATA2* mutation decreased virtually in parallel with the blast cell percentage, while the VAF of the *CDC25C* mutation hovered at a high level before transplantation. Thus, we hypothesized that the *GATA2* mutation induced leukaemia progression in this patient, whereas the *CDC25C* mutation was associated with the pre-leukaemic status. Another *GATA2* mutation (p.Leu359Val) was found in subject 18, with a VAF (0.94%), who showed only thrombocytopenia without any signs of leukaemia progression and who had a small subclone with a concurrent *CDC25C* mutation (Fig. 3c). Although *GATA2* mutations are detected in a small number of patients with FPD/AML, the findings described above suggest that mutation of *GATA2* is a key factor promoting disease progression in FPD/AML (Fig. 3d).

Biological consequences of *CDC25C* mutations. We next investigated the possible impact of *CDC25C* mutation on clonal selection and evolution. *CDC25C* is a phosphatase that prevents premature mitosis in response to DNA damage at the G2/M checkpoint, while it is constitutively phosphorylated at Ser216 throughout interphase by c-TAK1 (refs 8–10). When phosphorylated at Ser216, *CDC25C* binds to 14-3-3 protein¹¹, leading to sequestration of *CDC25C* to the cytoplasm and its inactivation. Ba/F3 cells were transduced with retroviruses encoding the wild-type or mutant *CDC25C* containing each of the individual mutations (p.Asp234Gly, p.Ala344Val, p.His437Asn and p.Ser216Ala), and assayed for the phosphorylation status, 14-3-3 protein-binding capacity and intracellular localization of each of these proteins. The Ser216Ala mutant form




Figure 1 | Mutation in *CDC25C* recurs in cases of FPD/AML. (a,b) Sanger sequencing of *CDC25C* mutations found in whole-exome sequencing is shown. Both forward and reverse traces were available for each mutation, but only one trace is shown above. The results of buccal mucosa, pre-leukaemic phase and leukaemic phase is demonstrated for subject 20 (a) and subject 21 (b), respectively. (c) The distribution of alterations is shown for the *CDC25C* protein. NES, a putative nuclear export signal domain between amino acids 177–200; NLS, a putative nuclear localization sequence domain consisting of amino acids 240–244.

of *CDC25C*, which lacks the phosphorylation site, was used as a negative control. In all of the mutated forms of *CDC25C*, the capacity for binding to c-TAK1 was reduced (Fig. 4a,b; Supplementary Fig. 9a,b), resulting in decreased phosphorylation of *CDC25C* at Ser216 (Fig. 4c). Consequently, the mutant proteins failed to bind 14-3-3 protein efficiently (Fig. 4d,e; Supplementary Fig. 8c,d) and remained in the nucleus even during interphase (Fig. 4f; Supplementary Figs 10 and 11). In accordance with these observations, *CDC25C* mutants enhanced mitotic entry, which was exaggerated by low-dose radiation-induced DNA damage (Fig. 4g,h; Supplementary Fig. 12; Supplementary Methods). These results suggest that mutation of *CDC25C* results in disruption of the DNA checkpoint machinery. Next, we investigated why mutation of *CDC25C* is a frequent genetic event in FPD/AML. It is known that *RUNX1* mutations suppress DNA damage repair and subsequent cell cycle arrest in hematopoietic cells by means of transcriptional suppression of several genes that are involved in DNA repair^{12,13}. We confirmed that FPD/AML-associated *RUNX1* mutations have similar effects, as we observed activation of the G2/M checkpoint mechanism in the presence of *RUNX1* mutations (Fig. 4i; Supplementary Fig. 13a,b). We found, however, that introduction of mutations in *CDC25C* resulted in enhanced mitosis entry, despite co-existence of *RUNX1*

mutations (Fig. 4i). Therefore, we speculated that compromised DNA damage checkpoint mechanisms caused by mutations in *CDC25C* may contribute to malignant transformation, in concert with increased genomic instability due to *RUNX1* mutations.

Discussion

Whole-exome sequencing, followed by targeted deep sequencing, identified novel aspects of the pathogenesis of malignant transformation in FPD/AML. First, the high frequency of *CDC25C* mutations in FPD/AML underscores their major role in the development of haematological malignancies in FPD/AML patients. To our knowledge, *CDC25C* mutations have not been reported previously and represent a new recurrent mutational target in haematological malignancies, although *CDC25C* mutations have been reported in some solid carcinomas with unknown significance^{14,15}. Furthermore, our functional assays support their biological significance, which is characterized by cell cycle progression and premature mitotic entry. Although the 5q31 minimally deleted region, in which *CDC25C* is located, is frequently detected in MDS, it seems to be associated with other oncogenic mechanisms since our functional assays suggested that *CDC25C* mutations in FPD/AML were gain-of-function type mutations that facilitate the mitotic entry by aberrant accumulation in the nucleus. Impaired DNA repair function mediated by germline *RUNX1* mutation may play a role in the generation of *CDC25C* mutations.

Evaluation of the allelic burden of mutated genes demonstrated that *CDC25C* mutations are found with high VAFs in FPD/AML-derived leukaemia and with low VAFs in cases of thrombocytopenia. Our hierarchical model and clonal selection highlighted that mutation of *CDC25C* defines an initial event during malignant transformation and predates subclonal mutations in *GATA2* and other genes. On the basis of the observation that four of the seven FPD/AML patients with *CDC25C* mutations have developed leukaemia and that *CDC25C* mutations were actually detected in the leukaemic subclones, we speculated that a FPD/AML patient with a *CDC25C* mutation, but without clinically evident leukaemia, is at high risk for the onset of leukaemic progression. Examination of the allelic burden of *CDC25C* mutation may thus serve to evaluate the risk of leukaemic progression in patients with FPD/AML.

Among the mutations found in FPD/AML, mutations in *GATA2* were identified in 3 of 13 individuals (subjects 18, 20 and 22). *GATA2* mutations were frequently identified in FPD/AML-derived leukaemia (2/7) and in a patient with thrombocytopenia who had a small subclone bearing a *CDC25C* mutation (1/6). Although reports on the clinical relevance of *GATA2* mutations in myeloid malignancy are limited, several lines of evidence in this respect have recently been reported. *GATA2* mutations are frequently found in a subgroup of patients with cytogenetically normal AML with biallelic *CEBPA* gene mutations¹⁶, which account for ~4% of AML. Germline *GATA2* mutations are also observed in disorders linked to an increased propensity for the development of MDS and AML, including Emberger syndrome, MonoMAC syndrome and dendritic cells, monocytes, B and natural killer cells deficiency^{17–20}. The alterations in *GATA2* (leading to p.Leu321His and p.Leu359Val), which were found in FPD/AML patients in this study, are located in the part of the gene encoding the N-terminal and C-terminal zinc-finger domains, respectively (Fig. 3d). Mutations affecting the identical amino acids have been reported in AML patients bearing *CEBPA* mutations and chronic myeloid leukaemia patients in blast crisis^{16,21}. Thus, *GATA2* mutation may contribute to AML progression in collaboration with *RUNX1* and/or *CDC25C* mutations. Furthermore, although




Figure 2 | Clonal evolution of FPD/AML-related myeloid disorders. (a,b) Observed variant allele fraction (VAF) of validated mutations are listed in Table 2, in both pre-leukaemic and leukaemic phases, are shown in diagonal plots (top) for subject 20 (a) and subject 21 (b). Predicted chronological behaviours in different leukemia subclones are depicted below each diagonal plot. Distinct mutation clusters are displayed by colour. The vertical axis represents cell proportion of each clone calculated by $VAF \times 2$ (%) (because all the mutations were heterozygous), regarding the whole bone marrow as 100%. (c) Mutation status of each bone marrow cell from subject 20 during the acute myeloid leukemia (AML) phase. The vertical axis represents each cell ($n = 63$) and the horizontal axis displays each gene mutation. Coloured columns show that the corresponding cell harbours gene mutation(s) as defined in Online Methods. Subclone numbers shown in the right row correspond to the numbers in the lower figure of a.




Figure 3 | GATA2 mutations in FPD/AML. The result of Sanger sequencing for GATA2 p.Leu321His mutation in subject 22 (a) and Leu359Val mutation in subject 18 (c) validated with subcloning strategy by methods shown in Supplementary Methods. (b) Variant allele fractions (VAFs) of *RUNX1*, *CDC25C* and *GATA2* mutation in subject 22 are demonstrated with the time course of treatment. Half the value of the blast cell percentage, which corresponds to the allele frequency of a heterozygous mutation, is also shown by a red bar. IA, idarubicine + Ara-C; AEM, Ara-C + etoposide + mitoxantrone; HDAC, high-dose Ara-C; uBMT, unrelated bone marrow transplantation. (d) Schematic representation of GATA2 mutations. GATA2 mutations that were identified in FPD/AML are displayed together with mutations found in AML with *CEBPA* mutation¹⁶ as well as in CML patients in blast crisis²¹. ZF, zinc-finger domain; NLS, a putative nuclear localization sequence domain.

another report identified somatic *CBL* mutation with acquired 11q uniparental disomy as a second hit as being responsible for leukaemic transformation in FPD/AML²², *CBL* mutations were not detected in our series of FPD/AML samples.

Although the precise pathogenetic roles of *CDC25C* mutations remain unclear, we presume that mutant *CDC25C* alleles confer a proliferative advantage under certain circumstances in which DNA repair machinery is compromised, such as that mediated by